Stockscreener 앱 받기
1.59
1.27%
0.02
시장 영업 전:
1.61
0.02
+1.26%
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
CRBU|Caribou Biosciences Inc|Price:1.585|Chg%:+0.015 - TradingKey
Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Caribou Biosciences Inc (CRBU) Cash Flow - TradingKey
BlackRock (NYSE: BLK) reports 7.2% beneficial stake in Caribou Biosciences (CRBU) - Stock Titan
Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Caribou Biosciences Inc (CRBU) Balance Sheet - TradingKey
Enterprise value to EBITDA forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Income Statement - TradingKey
Caribou Biosciences Inc (CRBU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Caribou Biosciences, Inc. Revenue Breakdown – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRBU|Caribou Biosciences Inc|Price:1.570|Chg%:-0.060 - TradingKey
Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBIT forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to earnings forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences secures e-poster spot for ANTLER abstract at PPLC 2026 - Traders Union
Caribou Biosciences Inc (CRBU) Institutional Confidence - TradingKey
Are medical stocks lagging Caribou Biosciences (CRBU) this year? - MSN
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? - Yahoo Finance
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, - GuruFocus
Caribou Biosciences stock holds focus on CRISPR therapies - ad-hoc-news.de
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Index - marketscreener.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Investing News Network
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Microcap Value Benchmark Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Value Benchmark - marketscreener.com
Caribou CEO set for fireside chat at cell therapy conference June 30 - Stock Titan
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire Inc.
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell Microcap Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
CRBUCaribou Biosciences Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences - The National Law Review
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Small Cap Completeness Index - marketscreener.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirt - The National Law Review
Caribou Biosciences, Inc. Actuals & Estimates (NASDAQ:CRBU) - TradingView
CRBU Forecast — Price Target — Prediction for 2027 - TradingView
Caribou Biosciences StockLong-term CRISPR strategy in focus - AD HOC NEWS
Caribou Biosciences Shareholders Decide Key Governance Matters - TipRanks
Caribou Biosciences (NASDAQ: CRBU) holders reject officer exculpation - Stock Titan
Caribou Biosciences Inc (CRBU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CRBU Q1 2026 Earnings: EPS Beat Offers Little Reprieve as Stock SlipsTech Earnings Analysis - newsline.com
Caribou Biosciences Inc (CRBU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses - CRISPR Medicine News
Investors who lost money on Caribou Biosciences, Inc.(CRBU) shou - GuruFocus
Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026 - Traders Union
Caribou Biosciences (CRBU) Slides 3.92%, Nears Critical Support at $1.51Catalyst Driven Stocks - newsline.com
Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA - Traders Union
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
1.97%
0.83%
자본화:
|
볼륨(24시간):